Literature DB >> 27207273

Use of Nonsteroidal Anti-Inflammatory Drugs for Symptomatic Treatment of Episodic Headache.

Giannapia Affaitati1, Paolo Martelletti2, Mariangela Lopopolo1, Claudio Tana3, Francesca Massimini4, Francesco Cipollone1, Domenico Lapenna5, Maria Adele Giamberardino1, Raffaele Costantini6.   

Abstract

INTRODUCTION: Primary headaches have high epidemiologic impact but their symptomatic treatment often remains problematic. Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently used, but their modality of employment and efficacy/differential efficacy are highly variable. This study investigated current NSAID use for episodic headache at an Italian headache center (January 2000 to February 2013).
METHODS: A retrospective evaluation was performed on 6,443 patient records: migraine (n = 2,330), tension-type headache (TTH; n = 807), and migraine plus TTH (n = 3,306).
RESULTS: Among migraine patients, 80% had used NSAIDs in the past year. Preferences were: nimesulide (57%), ketoprofen (25%), and ibuprofen (24%); complete efficacy was significantly higher than incomplete/absent efficacy (P < 0.0001). NSAIDs were replaced with triptans in 53% of patients at first visit; after 1 year there was a spontaneous significant return to NSAIDs (56%; P < 0.0005). Among TTH patients, 90% were NSAID users; preferences were: nimesulide (48%), ketoprofen (47%), and diclofenac (19%), with significantly higher complete vs. incomplete/absent efficacy (nimesulide and ketoprofen, P < 0.02). Replacement with analgesics was performed in 24% of patients; after 1 year, there was a 29% return to NSAIDs. Among migraine plus TTH patients, 89% were NSAID users. Preferences were: nimesulide (44%), ibuprofen (42%), and ketoprofen (38%), with significantly higher complete vs. incomplete/absent efficacy (0.001 < P < 0.0001). Replacement with analgesics was performed in 31% of patients; after 1 year, there was a 37% return to NSAIDs.
CONCLUSIONS: Nonsteroidal anti-inflammatory drug use in headache was higher than could be hypothesized based on guidelines, with NSAID preferences not entirely coinciding with international recommendations. This outcome suggests the need for greater awareness of all treatment options in headache by both patients and physicians.
© 2016 World Institute of Pain.

Entities:  

Keywords:  episodic headache; migraine; nonsteroidal anti-inflammatory drugs; symptomatic treatment; tension-type headache

Mesh:

Substances:

Year:  2016        PMID: 27207273     DOI: 10.1111/papr.12461

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  7 in total

Review 1.  Co-occurrence of pain syndromes.

Authors:  Giannapia Affaitati; Raffaele Costantini; Claudio Tana; Francesco Cipollone; Maria Adele Giamberardino
Journal:  J Neural Transm (Vienna)       Date:  2019-11-29       Impact factor: 3.575

2.  Effects of NSAIDs on the Release of Calcitonin Gene-Related Peptide and Prostaglandin E2 from Rat Trigeminal Ganglia.

Authors:  Vittorio Vellani; Giorgia Moschetti; Silvia Franchi; Chiara Giacomoni; Paola Sacerdote; Giada Amodeo
Journal:  Mediators Inflamm       Date:  2017-10-25       Impact factor: 4.711

Review 3.  Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.

Authors:  Maria Adele Giamberardino; Giannapia Affaitati; Francesco Cipollone; Paolo Martelletti; Raffaele Costantini
Journal:  J Pain Res       Date:  2017-12-08       Impact factor: 3.133

4.  Variables associated with use of symptomatic medication during a headache attack in individuals with tension-type headache: a European study.

Authors:  César Fernández-de-Las-Peñas; Maria Palacios-Ceña; Matteo Castaldo; Kelun Wang; Ángel Guerrero-Peral; Antonella Catena; Lars Arendt-Nielsen
Journal:  BMC Neurol       Date:  2020-02-01       Impact factor: 2.474

5.  Patients' preferences for headache acute and preventive treatment.

Authors:  Dimos D Mitsikostas; Ioanna Belesioti; Chryssa Arvaniti; Euthymia Mitropoulou; Christina Deligianni; Elina Kasioti; Theodoros Constantinidis; Manolis Dermitzakis; Michail Vikelis
Journal:  J Headache Pain       Date:  2017-10-06       Impact factor: 7.277

6.  Migraine and greater pain symptoms at 10-year follow-up among patients with major depressive disorder.

Authors:  Ching-I Hung; Chia-Yih Liu; Ching-Hui Yang; Shuu-Jiun Wang
Journal:  J Headache Pain       Date:  2018-07-17       Impact factor: 7.277

Review 7.  Myofascial trigger points in migraine and tension-type headache.

Authors:  Thien Phu Do; Gerda Ferja Heldarskard; Lærke Tørring Kolding; Jeppe Hvedstrup; Henrik Winther Schytz
Journal:  J Headache Pain       Date:  2018-09-10       Impact factor: 7.277

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.